文献速递临床免疫临床生化质量管理与危急值

浊度法C反应蛋白检测在南基伍评估早发型新生儿败血症

Evaluation of a turbidimetric C-reactive protein assay to monitor early-onset neonatal sepsis in South Kivu (Democratic Republic of the Congo).
PubMed 文献 · Clin Chem Lab Med · 2020-05-05

本研究在刚果(金)南基伍省布卡武省立总医院新生儿重症监护病房纳入148例新生儿,评估一种基于Intralipid®与磷酸胆碱颗粒相互作用的非商业浊度法CRP检测用于诊断和监测早发型新生儿败血症(EOS)。62/148(41.9%)为血培养确诊EOS,不同出生体重类别间血清CRP斜率不同,且(CRP 48 h−CRP 12 h)差值与出生体重可预测败血症新生儿结局。该检测简便且价格极低,适合发展中国家使用。

要点

  • 148例新生儿中62/148(41.9%)为血培养确诊EOS。
  • 不同出生体重类别间血清CRP斜率存在差异。
  • (CRP 48 h−CRP 12 h)差值与出生体重可预测EOS新生儿结局。

核心结论

  • 该浊度法CRP检测是可用于撒哈拉以南非洲EOS管理的新型潜在工具。
  • 检测简便且价格极低,非常适合发展中国家。

研究设计与样本

  • 在刚果(金)南基伍省布卡武省立总医院新生儿重症监护病房纳入148例新生儿,用于诊断和监测EOS。
  • CRP采用基于CRP与含磷酸胆碱颗粒(Intralipid®)相互作用的功能性浊度法测定。

主要发现

  • 62/148(41.9%)病例为血培养确诊的EOS。
  • 不同出生体重类别间观察到不同的血清CRP斜率。
  • 血清(CRP 48 h−CRP 12 h)差值与出生体重可预测这些败血症新生儿的结局。

关键数值与推荐

  • EOS定义为生后第一个月内菌血症并伴有全身感染体征。
  • 血培养确诊EOS为62/148(41.9%)。

临床怎么用

  • 该浊度法CRP检测可用于资源有限地区EOS的诊断与监测。
  • 可结合出生体重与(CRP 48 h−CRP 12 h)差值评估败血症新生儿结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Neonatal sepsis, a condition defined as bacteremia within the first month of life accompanied by signs of systemic infection, is the most preventable cause of infant mortality in sub-Saharan Africa. Despite the development of new infection markers, C-reactive protein (CRP) is the most extensively studied acute phase reactant so far and the preferred index in many neonatal intensive care units (NICUs). The aim of the present study was to evaluate an affordable, non-commercial turbidimetric CRP assay for monitoring early-onset neonatal sepsis (EOS). METHODS: A total of 148 neonates admitted at the NICU of the Hôpital Provincial Général de Référence de Bukavu to diagnose and to monitor EOS were enrolled in the study. CRP was assayed using a functional turbidimetric assay based on the interaction of CRP with phosphocholine containing particles (Intralipid®). RESULTS: In total, 62/148 (41.9%) cases were identified as blood culture-proven EOS. Different serum CRP slopes were observed among the different birth weight categories. Moreover, the serum (CRP 48 h-CRP 12 h) difference and the birth weight predicted the outcome of these septic newborns. CONCLUSIONS: Our turbidimetric CRP assay is a potential novel tool that can be used in the management of EOS in sub-Saharan Africa. The simplicity of the assay and the extremely low price make the CRP method very well suited for developing countries.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Mulinganya G, Balolebwami S, Zigabe S, et al. Evaluation of a turbidimetric C-reactive protein assay to monitor early-onset neonatal sepsis in South Kivu (Democratic Republic of the Congo). Clin Chem Lab Med. 2020. PMID: 32374279. doi:10.1515/cclm-2020-0309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。